Burosumab, a fully human monoclonal antibody, targets the excess FGF23 activity of XLH, thereby increasing renal phosphate reabsorption and enhancing intestinal phosphate absorption through the production of 1,25-dihydroxyvitamin D, the active form of vitamin D (4, 12). The gene discussed is FGF23; the disease is X-linked hypophosphatemia.